Feb 24, 2024, 16:34
Chul Kim: What are other relevant targets for ADC therapy in NSCLC?
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter:
“What are other relevant targets for Antibody Drug Conjugates (ADCs) therapy in Non-small cell lung cancer (NSCLC)? Farletuzumab ecteribulin (FRalpha), patritumab deruxtecan (HER3), SGN-B6A (integrin beta-6) are being actively investigated. Awesome talk by Maria Antonia Vélez (hematology/oncology fellow at UCLA)!”
Source: Chul Kim/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 23, 2024, 21:21
Dec 23, 2024, 21:19
Dec 23, 2024, 21:16
Dec 23, 2024, 21:09
Dec 23, 2024, 20:37
Dec 23, 2024, 20:18
Dec 23, 2024, 20:14